BRPI9908914B1 - iron-dextran compound for use as a component in a therapeutic composition, for the prophylaxis or treatment of iron deficiency; process for producing said iron-dextran compound and using said compound for preparing a parenterally administrable therapeutic composition. - Google Patents

iron-dextran compound for use as a component in a therapeutic composition, for the prophylaxis or treatment of iron deficiency; process for producing said iron-dextran compound and using said compound for preparing a parenterally administrable therapeutic composition.

Info

Publication number: BRPI9908914B1
Authority: BR; Brazil
Prior art keywords: iron; compound; therapeutic composition; dextran; prophylaxis
Prior art date: 1998-03-25

Application number

BRPI9908914-9A

Other languages

Portuguese (pt)

Inventor

Hans Berg Andreasen

Lars Christensen

Original Assignee

Pharmacosmos Holding As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-25

Filing date

1999-03-24

Publication date

2012-06-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8093321&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9908914(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-03-24 Application filed by Pharmacosmos Holding As filed Critical Pharmacosmos Holding As

2000-11-21 Publication of BRPI9908914A publication Critical patent/BRPI9908914A/en

2012-06-12 Publication of BRPI9908914B1 publication Critical patent/BRPI9908914B1/en

2021-07-06 Publication of BRPI9908914B8 publication Critical patent/BRPI9908914B8/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Hematology (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

BRPI9908914 1998-03-25 1999-03-24 iron-dextran compound for use as a component in a therapeutic composition, for the prophylaxis or treatment of iron deficiency; process for producing said iron-dextran compound and using said compound for preparing a parenterally administrable therapeutic composition. BRPI9908914B8 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK199800420A DK172860B1 (en)	1998-03-25	1998-03-25	Iron dextran compound for use as a component of a therapeutic agent for the prevention or treatment of iron man
PCT/DK1999/000160 WO1999048533A1 (en)	1998-03-25	1999-03-24	An iron-dextran compound for use as a component in a therapeutical composition for prophylaxis or treatment of iron-deficiency, a process for producing said iron-dextran compound and use of said compound for the preparation of a parenterally administrable therapeutical composition

Publications (3)

Publication Number	Publication Date
BRPI9908914A BRPI9908914A (en)	2000-11-21
BRPI9908914B1 true BRPI9908914B1 (en)	2012-06-12
BRPI9908914B8 BRPI9908914B8 (en)	2021-07-06

Family

ID=8093321

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI9908914 BRPI9908914B8 (en)	1998-03-25	1999-03-24	iron-dextran compound for use as a component in a therapeutic composition, for the prophylaxis or treatment of iron deficiency; process for producing said iron-dextran compound and using said compound for preparing a parenterally administrable therapeutic composition.

Country Status (27)

Country	Link
US (1)	US6291440B1 (en)
EP (1)	EP1066056B2 (en)
JP (1)	JP4558198B2 (en)
KR (1)	KR100612071B1 (en)
CN (1)	CN1147322C (en)
AR (1)	AR015738A1 (en)
AT (1)	ATE220560T1 (en)
AU (1)	AU740432B2 (en)
BR (1)	BRPI9908914B8 (en)
CA (1)	CA2322633C (en)
CZ (1)	CZ300823B6 (en)
DE (1)	DE69902154T3 (en)
DK (2)	DK172860B1 (en)
EA (1)	EA003427B1 (en)
ES (1)	ES2180279T5 (en)
HU (1)	HU228483B1 (en)
ID (1)	ID26778A (en)
NO (1)	NO329591B1 (en)
NZ (1)	NZ505983A (en)
PL (1)	PL195582B1 (en)
PT (1)	PT1066056E (en)
SI (1)	SI1066056T2 (en)
SK (1)	SK284499B6 (en)
TR (1)	TR200002733T2 (en)
UA (1)	UA70939C2 (en)
WO (1)	WO1999048533A1 (en)
ZA (1)	ZA200004016B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK173138B1 (en)	1998-11-20	2000-02-07	Pharmacosmos Holding As	Process for Preparing an Iron Dextran Compound, Iron Dextran Compound Prepared by the Process, Pharmaceutical
US7871597B2 (en)	1999-04-09	2011-01-18	Amag Pharmaceuticals, Inc.	Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
WO2000061191A2 (en) *	1999-04-09	2000-10-19	Advanced Magnetics, Inc.	Heat stable coated colloidal iron oxides
KR20020003344A (en) *	2001-12-17	2002-01-12	유형선	Formulation of iron supplement for oral administration
EP1492821B1 (en) *	2002-04-09	2006-08-02	Pharmacosmos Holding A/S	Iron dextrin compounds for the treatment of iron deficiency anaemia
DE10249552A1 (en)	2002-10-23	2004-05-13	Vifor (International) Ag	Water-soluble iron-carbohydrate complexes, their preparation and medicaments containing them
US20060116349A1 (en) *	2003-03-14	2006-06-01	Luitpold Pharmaceuticals, Inc.	Methods and compositions for administration of iron for the treatment of restless leg syndrome
DE102004031181A1 (en) *	2004-06-28	2006-01-19	Vifor (International) Ag	phosphate adsorbent
ITMO20050056A1 (en)	2005-03-15	2006-09-16	Biofer Spa	PROCESS FOR THE PREPARATION OF TRIVALENT IRON COMPLEXES WITH MONO-, DI- AND POLISACCARIDI SUGARS.
EP1757299A1 (en)	2005-08-25	2007-02-28	Vifor (International) Ag	Complexes of iron III for treating iron deficiencies in patients with inflammatory bowel disease
CA2953964A1 (en)	2006-01-06	2007-07-19	Luitpold Pharmaceuticals, Inc.	Methods and compositions for administration of iron
EP1947120A1 (en) *	2007-01-19	2008-07-23	Vifor (International) Ag	Iron-carbohydrate complex compounds
EP1997833A1 (en) *	2007-05-29	2008-12-03	Vifor (International) Ag	Water-soluble ferric carbohydrate derivative complexes, their manufacture and medicines containing these
CN101585887B (en) *	2008-05-22	2011-12-14	中国科学院过程工程研究所	Method for desalting and concentrating dextriferron complex compound aqueous solution by nanofiltration technology
WO2010108493A1 (en)	2009-03-25	2010-09-30	Pharmacosmos Holding A/S	A stable iron oligosaccharide compound
CN101967205B (en) *	2010-10-12	2013-04-17	滨州学院	Beta-dextriferron composite and preparation method thereof
EP2537866A1 (en) *	2011-06-21	2012-12-26	Serumwerk Bernburg AG	Hydroxyethyl starch derivatives, method for manufacturing the same and therapeutical uses thereof
PL398814A1 (en)	2012-04-16	2013-10-28	Uniwersytet Jagiellonski	The use of dextran derivatives for the prevention or treatment of anemia
WO2015198304A1 (en)	2014-06-22	2015-12-30	Dexcel Pharma Technologies Ltd.	Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
DK3212182T3 (en) *	2014-10-27	2019-08-05	Pharmacosmos Holding As	TREATMENT OR PREVENTION OF ANHEMIA IN PREGNANT NON-HUMAN MAMMALS AND PROCEDURES
KR20200044030A (en) *	2017-09-11	2020-04-28	파르마코스모스 홀딩 에이/에스	Therapeutic iron complex
CN109646454A (en) *	2018-12-29	2019-04-19	博瑞生物医药（苏州）股份有限公司	The preparation method of isomaltose acid anhydride iron 1000
CN110183548B (en) *	2019-06-28	2021-05-18	瑞普（天津）生物药业有限公司	A kind of preparation method and application of low molecular weight glucan iron
MX2024001607A (en)	2021-08-03	2024-02-27	Pharmacosmos Holding As	Iron complex compounds for subcutaneous use in therapy of iron deficiency in companion animals.
WO2026017897A1 (en)	2024-07-18	2026-01-22	Malian Biologicals Gmbh	Iron supplementation in affective disorders and/or post-traumatic stress disorder (ptsd) and/or serotonin-dependent diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE24642E (en)		1959-04-28		Therapeutic preparations of iron
DK117730A (en)
US2885393A (en)	1956-02-24	1959-05-05	R K Laros Company	Dextran-iron complex and process for making same
US3093545A (en)	1960-08-29	1963-06-11	Armour Pharma	Therapeutic iron-dextran preparations
US3234209A (en) *	1963-09-13	1966-02-08	Chemicals Inc	Process for making iron hydrogenated dextran
DE1293144B (en) *	1964-11-04	1969-04-24	Hausmann Ag Labor	Process for the production of complex compounds of iron with sorbitol, gluconic acid and an oligosaccharide
GB1183940A (en)	1966-10-22	1970-03-11	Fisons Pharmaceuticals Ltd	Ferric Hydroxide Complexes
GB1200902A (en)	1967-05-13	1970-08-05	Fisons Pharmaceuticals Ltd	Iron-dextran complexes
CH507993A (en)	1967-07-13	1971-05-31	Kutnowskie Zakl Farma	Ferric complexes of hydrogenated dextrans for - parenteral and/or enteral treatment of iron-deficiency
DK129353B (en)	1968-04-29	1974-09-30	Fisons Pharmaceuticals Ltd	Analogous process for the preparation of a ferric hydroxide-dextran derivative complex or a solution thereof.
US3697502A (en)	1969-11-03	1972-10-10	Christensen Henry M	Method of making iron dextran-preparations
GB1562913A (en) *	1976-06-16	1980-03-19	Fisons Ltd	Fractionating fluid mixtures of dextrans
DE3422249A1 (en) *	1984-06-15	1985-12-19	Pfeifer & Langen, 5000 Köln	WATER-SOLUBLE IRON DEXTRANE AND METHOD FOR THE PRODUCTION THEREOF
US4827945A (en)	1986-07-03	1989-05-09	Advanced Magnetics, Incorporated	Biologically degradable superparamagnetic materials for use in clinical applications
US5102652A (en)	1986-07-03	1992-04-07	Advanced Magnetics Inc.	Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
IT1263831B (en) *	1993-01-29	1996-09-04	Paolo Chiesi	MULTI-COMPONENT INCLUSION COMPLEXES WITH HIGH SOLUBILITY CONSTITUTED BY A BASIC-TYPE DRUG, AN ACID AND A CYCLODEXTRINE
RU2093577C1 (en) *	1993-11-04	1997-10-20	Государственный институт кровезаменителей и медицинских препаратов	Method of dextran preparing
GB9402029D0 (en) *	1994-02-03	1994-03-30	Smithkline Beecham Plc	Novel formulation
US5624668A (en) *	1995-09-29	1997-04-29	Luitpold Pharmaceuticals, Inc.	Iron dextran formulations

1998
- 1998-03-25 DK DK199800420A patent/DK172860B1/en not_active IP Right Cessation
1999
- 1999-03-24 PT PT99908785T patent/PT1066056E/en unknown
- 1999-03-24 DK DK99908785T patent/DK1066056T4/en active
- 1999-03-24 ES ES99908785T patent/ES2180279T5/en not_active Expired - Lifetime
- 1999-03-24 PL PL99343164A patent/PL195582B1/en unknown
- 1999-03-24 AU AU28273/99A patent/AU740432B2/en not_active Ceased
- 1999-03-24 UA UA2000095459A patent/UA70939C2/en unknown
- 1999-03-24 JP JP2000537579A patent/JP4558198B2/en not_active Expired - Lifetime
- 1999-03-24 TR TR2000/02733T patent/TR200002733T2/en unknown
- 1999-03-24 NZ NZ505983A patent/NZ505983A/en not_active IP Right Cessation
- 1999-03-24 SI SI9930103T patent/SI1066056T2/en unknown
- 1999-03-24 HU HU0101189A patent/HU228483B1/en unknown
- 1999-03-24 EA EA200000981A patent/EA003427B1/en not_active IP Right Cessation
- 1999-03-24 CA CA002322633A patent/CA2322633C/en not_active Expired - Fee Related
- 1999-03-24 BR BRPI9908914 patent/BRPI9908914B8/en not_active IP Right Cessation
- 1999-03-24 KR KR1020007010563A patent/KR100612071B1/en not_active Expired - Lifetime
- 1999-03-24 SK SK1409-2000A patent/SK284499B6/en not_active IP Right Cessation
- 1999-03-24 EP EP99908785A patent/EP1066056B2/en not_active Expired - Lifetime
- 1999-03-24 AR ARP990101309A patent/AR015738A1/en active IP Right Grant
- 1999-03-24 AT AT99908785T patent/ATE220560T1/en active
- 1999-03-24 CN CNB998042498A patent/CN1147322C/en not_active Expired - Lifetime
- 1999-03-24 CZ CZ20003535A patent/CZ300823B6/en not_active IP Right Cessation
- 1999-03-24 WO PCT/DK1999/000160 patent/WO1999048533A1/en not_active Ceased
- 1999-03-24 ID IDW20001881A patent/ID26778A/en unknown
- 1999-03-24 DE DE69902154T patent/DE69902154T3/en not_active Expired - Lifetime
- 1999-03-24 US US09/509,454 patent/US6291440B1/en not_active Expired - Lifetime
2000
- 2000-08-07 ZA ZA200004016A patent/ZA200004016B/en unknown
- 2000-08-18 NO NO20004151A patent/NO329591B1/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2180279T5 (en)	2009-05-05
DE69902154D1 (en)	2002-08-22
HK1033426A1 (en)	2001-08-31
PL195582B1 (en)	2007-10-31
SK14092000A3 (en)	2001-04-09
CN1147322C (en)	2004-04-28
EP1066056B2 (en)	2008-12-10
SI1066056T1 (en)	2002-12-31
HU228483B1 (en)	2013-03-28
ID26778A (en)	2001-02-08
HUP0101189A2 (en)	2001-08-28
JP2002507582A (en)	2002-03-12
DK42099A (en)	1999-08-16
DK1066056T3 (en)	2002-10-14
UA70939C2 (en)	2004-11-15
NO329591B1 (en)	2010-11-15
DK1066056T4 (en)	2009-04-14
EA200000981A1 (en)	2001-02-26
CZ300823B6 (en)	2009-08-19
CA2322633A1 (en)	1999-09-30
NO20004151L (en)	2000-08-18
KR20010034641A (en)	2001-04-25
KR100612071B1 (en)	2006-08-11
BRPI9908914B8 (en)	2021-07-06
AU2827399A (en)	1999-10-18
EP1066056B1 (en)	2002-07-17
US6291440B1 (en)	2001-09-18
AR015738A1 (en)	2001-05-16
CN1293577A (en)	2001-05-02
SK284499B6 (en)	2005-05-05
HUP0101189A3 (en)	2003-12-29
EP1066056A1 (en)	2001-01-10
CZ20003535A3 (en)	2001-04-11
NO20004151D0 (en)	2000-08-18
ATE220560T1 (en)	2002-08-15
ZA200004016B (en)	2001-07-25
NZ505983A (en)	2002-11-26
TR200002733T2 (en)	2000-12-21
ES2180279T3 (en)	2003-02-01
EA003427B1 (en)	2003-04-24
JP4558198B2 (en)	2010-10-06
PT1066056E (en)	2002-12-31
DE69902154T3 (en)	2009-07-09
BRPI9908914A (en)	2000-11-21
CA2322633C (en)	2009-01-27
PL343164A1 (en)	2001-07-30
DK172860B1 (en)	1999-08-16
AU740432B2 (en)	2001-11-01
WO1999048533A1 (en)	1999-09-30
DE69902154T2 (en)	2003-03-06
SI1066056T2 (en)	2009-04-30

Publication	Publication Date	Title
BRPI9908914B1 (en)	2012-06-12	iron-dextran compound for use as a component in a therapeutic composition, for the prophylaxis or treatment of iron deficiency; process for producing said iron-dextran compound and using said compound for preparing a parenterally administrable therapeutic composition.
WO2006068729A3 (en)	2007-01-18	Methods and compositions for enhancing iron absorption
WO2000074662A3 (en)	2002-03-14	Arthritis treatment
BRPI0414544A (en)	2006-11-07	2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
PT1143967E (en)	2005-01-31	USE OF ANTICONVULSIVE DERIVATIVES FOR THE TREATMENT OF SAWS IN SALVAS
MY126527A (en)	2006-10-31	Novel dihydropyrimidines
BG108443A (en)	2005-03-31	Substituted oxazoliidinones for combinational therapy
PT1459751E (en)	2005-11-30	(S, S) -REBOXETINE FOR TREATING THE ENZACHERS
CA2376596A1 (en)	2001-01-04	Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
CY1109437T1 (en)	2014-08-13	B-GLYCANES AND SPECIFIC SIGNIFICANCE COMPOSITIONS
BRPI0416605A (en)	2007-01-30	compound, process for preparing a compound, use of a compound, methods of inhibiting trk activity, treating or prophylaxis of cancer, and producing an antiproliferative effect on a warm-blooded animal and pharmaceutical composition
PL330496A1 (en)	1999-07-05	Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy
IL142900A0 (en)	2002-04-21	Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
BR0313792A (en)	2005-07-12	Use of erythropoietin protein, method for treatment of iron distribution disorders in diabetes and medicine for its treatment
BRPI0507423A (en)	2007-06-26	composition for use in washing or treating fabrics and a process for making such composition
BRPI0512636A (en)	2008-03-25	iron sulphate based phosphate adsorbent
BRPI0406596A (en)	2005-12-20	Methods for treating joint pain and improving sleep using an estrogen agonist / antagonist
NO20013493L (en)	2001-09-17	Use of neurotrophin and its analogues in the treatment of gastrointestinal hypomotility disorders
WO2003039453A3 (en)	2003-12-04	Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
DK1107795T3 (en)	2003-03-24	Thiomolybdate associated with at least one carbohydrate and its use in the prevention or treatment of diseases characterized by aberrant vascularization such as cancer, wet type macular degeneration, rheumatoid arthritis
PL368948A1 (en)	2005-04-04	Process and composition for treating wood
EE05211B1 (en)	2009-10-15	Use of saredutant and its pharmaceutically acceptable salts in the preparation of medicaments useful for the treatment or prevention of mood disorders, adaptive disorders, or mixed depressive disorders.
WO1999011256A8 (en)	1999-08-05	L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof
BR9900821A (en)	1999-12-28	Process for improving the appearance of a floor polishing composition, vehicle composition for floor polishing, and use of divalent copper ion.
BR9913936A (en)	2001-06-19	Process to prevent or treat periodontitis in a mammal, and, use of an antimicrobial composition

Legal Events

Date	Code	Title	Description
2012-06-12	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/06/2012, OBSERVADAS AS CONDICOES LEGAIS.
2021-07-06	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/03/99, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO
2022-06-21	B21A	Patent or certificate of addition expired [chapter 21.1 patent gazette]	Free format text: PATENTE EXTINTA EM 24.03.2019